Cargando…
Is anti-hormonal treatment in DCIS of the breast a need?
Ductal carcinomas in situ (DCIS) represent one fifth of all detected breast cancers. The detection of DCIS can be regarded as collateral damage of breast cancer screening. The treatment of DCIS is based on surgery with or without radiotherapy. Women treated for DCIS have a 10 years survival of 98 %....
Autor principal: | Tjalma, WAA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universa Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172575/ https://www.ncbi.nlm.nih.gov/pubmed/28003873 |
Ejemplares similares
-
Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision
por: Tjalma, W.A.A.
Publicado: (2015) -
HPV negative cervical cancers and primary HPV screening
por: Tjalma, WAA
Publicado: (2018) -
The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast
por: Villanueva, Hugo, et al.
Publicado: (2018) -
Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022) -
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
por: Bergholtz, Helga, et al.
Publicado: (2020)